[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554759":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":18,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":18,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":18,"overallStatus":40,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Maintenance Therapy","EXPERIMENTAL","Patients were treated by Zanubrutinib plus Lenalidomide as Maintenance Therapy",[13],"Drug: Zanubrutinib plus Lenalidomide as Maintenance Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"No maintenance Therapy","NO_INTERVENTION","Patients received no maintenance Therapy",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Zanubrutinib plus Lenalidomide as Maintenance Therapy","Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay",[9],[26],"Zanubrutinib plus Lenalidomide",[28],{"name":29,"affiliation":5,"role":30},"qlr2007@126.com Qian, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},"Liren Qian, PhD","CONTACT","+861066947192","qlr2007@126.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":18,"email":36},"Liren Qian, M.D.","+861066947194",{"type":30,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Liren Qian","Vice Director","100554759","phase-2-zanubrutinib-and-lenalidomide-as-maintenance-therapy-in-dlbcl-100554759",false,"NCT06503263","Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL","Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has recieved complete remission and has completed planed courses of chemotherapy\n* Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma)； Hemoglobin ≥ 8 g\u002FdL. Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;\n* Pregnant or lactating women","ALL","14 Years",{"count":69,"type":70},240,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.",[76],"Diffuse Large B-cell Lymphoma","2024-09-05",{"date":79,"type":80},"2024-09-19","ACTUAL",{"date":82,"type":80},"2024-08-30",{"date":84,"type":70},"2030-12-30",{"name":5,"class":6},1]